BPC guest lineup "star" force announced, promoting the acceleration of innovation of original research drugs
Time of Update: 2022-05-18
>Shi Jun, School of Life Science and Technology, Kunming University of Science and Technology, Ph . Vice President Li Jingrong, CTO of Jinfang Pharmaceutical, General Manager
$3 Billion Oral Antidiabetic Drugs!
Time of Update: 2022-05-18
Prior to this, Lepu Pharmaceuticals had won the compound antihypertensive drug Valsartan Amlodipine Tablets (I), and the total sales of this product in Chinese public medical institutions and Chinese urban physical pharmacies exceeded 2 billion yuan .
The development process of domestic improved new drugs is accelerating, and the number of applications is continuing to grow
Time of Update: 2022-05-18
In fact, in recent years, with the improvement of the research and development capabilities of domestic pharmaceutical companies, some high-barrier technologies, such as liposomes, microspheres, oral dissolving membranes, micelles, transdermal patches, etc.
The new anti-tumor drug introduced by Lee's Big Pharma has been approved for marketing
Time of Update: 2022-05-18
From https:// Good News Group's anti-tumor drug for the treatment of advanced Hodgkin's lymphoma - Natulan® has been accepted by the NMPA, and the application for priority review will be submitted in May.
Multi-pharmaceutical companies issued an announcement: anti-tumor drugs were approved for clinical trials
Time of Update: 2022-05-18
"TQB2930" for injection has been approved by the China National Medical Products Administration to conduct drug clinical trials for the treatment of patients with advanced malignant tumors .
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Junshi Launches Head-to-Head Phase III Clinical Trial of New Crown Oral Drug VV116 Compared with Pfizer's Paxlovid
Time of Update: 2022-05-18
On April 19, the website of the China Clinical Trials Registry announced a multi-center, single-blind, randomized, controlled clinical study of Junshi Bio/Wangshan Wangshui VV116 head-to-head versus Pfizer Paxlovid in the early treatment of mild to severe new coronary pneumonia .
Recently, local pharmaceutical companies have successively reviewed a number of large varieties of drugs
Time of Update: 2022-05-18
Data shows that in 2020, the market size of the terminal piracetam injection in China's public medical institutions is close to 2 billion yuan, a year-on-year increase of 37.
100 million-level best-selling cardiovascular drug Chengdu Bitedigoxin Tablets is the first to review
Time of Update: 2022-05-18
On April 19, NMPA's official website released the latest information on approved drugs, and Chengdu Beite Pharmaceutical's digoxin tablets were the first to be reviewed .
New progress in drug research on fish enterohepatic inflammation
Time of Update: 2022-05-17
>TCMID ( Traditional Chinese Medicines Integrated Database ) to predict the effective treatment of intestinal and liver inflammation
The large variety of anti-gout was "cut in half", and 4 new drugs of class 1 of traditional Chinese medicine were strongly filled
Time of Update: 2022-05-17
Figure 1: Market size of chemical anti-gout preparations in recent years (unit: 100 million yuan) Source: Minet.
The head of Novartis Innovative Drugs China confirmed!
Time of Update: 2022-05-17
Novartis' business "two-in-one" innovative drug China head confirmed In the past two years, multinational pharmaceutical companies have set off a new round of organizational restructuring, with frequent personnel changes .
5 kinds of the world's first batch of new drugs approved by PMDA in the first quarter of 2022
Time of Update: 2022-05-17
According to the classification of drug treatment categories, the drug categories with the largest number of new drug approvals are anti-tumor drugs, reproductive system drugs, sex hormones and skeletal and muscle drugs, with 13, 11 and 4 drugs respectively .
In 2022, the "close relatives" of Class 1 innovative drugs will accelerate the launch of the outbreak
Time of Update: 2022-05-17
From the perspective of new improved chemical drugs (excluding new indications) approved from 2020 to the present, there are a total of levoornidazole tablets from Shenghe Pharmaceuticals, olanzapine oral dissolving film from Hansoh, and montelukast from Qilu Pharmaceuticals.
Sanofi Announces Summary Data from Clinical Trial of New Transplant Drug Rezurock
Time of Update: 2022-05-17
Pooled analyses from the ROCKstar (KD025-213) and KD025-028 studies show a very strong, but not generalized, correlation between organ clinical response measures and clinically meaningful changes in PRO in patients treated with Rezurock .
The State Food and Drug Administration has approved 29 new coronavirus antigen detection reagents
Time of Update: 2022-05-17
As of April 20, the State Food and Drug Administration has approved 29 new coronavirus antigen detection reagent products .
The $100 billion rare disease drug market is "attractive", and pharmaceutical companies have stepped up to enter the "enclosure"
Time of Update: 2022-05-17
, the main indications are rare diseases and tumors, and the company is currently promoting the research projects to clinical research . In early January this year, AstraZeneca announced that its rare
Nature: New coronavirus broad-spectrum specific drugs for new targets, without fear of mutation, can prevent and treat various mutant infections
Time of Update: 2022-05-17
>With the increase in the number of infected people, today's new coronavirus (SARS-CoV-2) has accumulated a large number of mutations and evolved into Delta and Omicron, which are more infectious and have immune escape ability. variant strain
Chia Tai Tianqing's onslaught of innovative drugs This year, 7 class 1 new drugs were approved for clinical use
Time of Update: 2022-05-17
On April 19, CDE's official website showed that Chia Tai Tianqing's Class 1 new drug TQH2722 injection was approved for clinical use and is intended to be used for the treatment of atopic dermatitis .
This pharmaceutical company has another new ADC drug for clinical application!
Time of Update: 2022-05-16
Specifically, BAT8009, which was also approved for clinical use in April, is a B7H3-targeting antibody-drug conjugate (ADC) developed by Bio-Tech, which is intended to be developed for the treatment of solid tumors .
